Gates $9.9M backs Evotec AI-driven push for faster, safer next-gen tuberculosis therapies

Evotec SE, a Hamburg, Germany-based biotechnology company focused on drug discovery and development, has announced a pair of two-year grants totaling $9.9 million from the Gates Foundation to support tuberculosis research in Hamburg, Germany. The funding backs research to discover novel small-molecule treatments and the evaluation of advanced drug combinations for clinical trials. Using AI-enabled platforms, the work aims to accelerate safer, shorter TB regimens, including long-acting injectables, reducing treatment burden, addressing drug resistance, and improving outcomes for millions affected by tuberculosis worldwide.